Outset Medical Inc. (OM)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Shareholders that Lost Money on Outset Medical, Inc. (OM) Should Contact Levi & Korsinsky About Securities Fraud Investigation - OM
NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.
Levi & Korsinsky Announces an Investigation on Behalf of Outset Medical, Inc. (OM) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / August 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Outset Medical, Inc. ("Outset Medical") (NASDAQ:OM) concerning possible violations of federal securities laws. Outset Medical reported its second-quarter financial results on August 7, 2024, revealing a notable decrease in revenue and a downward adjustment in its full-year guidance.
Why Is Outset Medical (OM) Stock Down 34% Today?
Outset Medical (NASDAQ: OM ) stock is taking a beating on Thursday after the medical technology company announced earnings results for the second quarter of the year. The Outset Medical earnings report starts with an adjusted EPS of -47 cents.
Outset Medical, Inc. (OM) Q2 2024 Earnings Call Transcript
Outset Medical, Inc. (NASDAQ:OM ) Q2 2024 Earnings Conference Call August 7, 2024 5:00 PM ET Company Participants Jim Mazzola - Head, Investor Relations Leslie Trigg - Chair & Chief Executive Officer Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Rick Wise - Stifel Shagun Sing - RBC Capital Markets Suraj Kalia - Oppenheimer Kristen Stewart - CL King Stephanie Piazzola - Bank of America Securities Drew Ranieri - Morgan Stanley Josh Jennings - TD Cowen Operator Ladies and gentlemen, thank you for standing by. Welcome to Outset Medical Second Quarter 2024 Earnings Conference Call.
Outset Medical, Inc. (OM) Reports Q2 Loss, Misses Revenue Estimates
Outset Medical, Inc. (OM) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.69 per share a year ago.
Will Outset Medical, Inc. (OM) Report Negative Earnings Next Week? What You Should Know
Outset Medical (OM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Outset Medical (OM) Upgraded to Buy: What Does It Mean for the Stock?
Outset Medical (OM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Outset Medical, Inc. (NASDAQ:OM) General Counsel Sells $10,491.16 in Stock
Outset Medical, Inc. (NASDAQ:OM – Get Free Report) General Counsel John L. Brottem sold 2,972 shares of the stock in a transaction on Thursday, May 16th. The shares were sold at an average price of $3.53, for a total value of $10,491.16. Following the sale, the general counsel now owns 243,875 shares in the company, valued at $860,878.75. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Outset Medical Stock Performance Shares of OM opened at $3.61 on Monday. The company has a quick ratio of 5.32, a current ratio of 6.42 and a debt-to-equity ratio of 2.11. Outset Medical, Inc. has a one year low of $1.92 and a one year high of $24.13. The business has a fifty day moving average of $2.55 and a 200 day moving average of $3.76. Outset Medical (NASDAQ:OM – Get Free Report) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.03). The firm had revenue of $30.51 million for the quarter, compared to the consensus estimate of $30.40 million. Outset Medical had a negative net margin of 134.93% and a negative return on equity of 120.67%. As a group, sell-side analysts anticipate that Outset Medical, Inc. will post -2.23 earnings per share for the current fiscal year. Analyst Ratings Changes A number of brokerages have recently issued reports on OM. BTIG Research began coverage on Outset Medical in a report on Monday, April 8th. They set a “buy” rating and a $6.00 price target on the stock. CL King raised shares of Outset Medical from a “neutral” rating to a “buy” rating and set a $6.00 price target on the stock in a report on Friday, April 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $5.42. Read Our Latest Analysis on OM Institutional Investors Weigh In On Outset Medical Several hedge funds and other institutional investors have recently modified their holdings of OM. State Board of Administration of Florida Retirement System boosted its position in shares of Outset Medical by 33.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 18,842 shares of the company’s stock worth $42,000 after purchasing an additional 4,720 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Outset Medical by 1,317.7% in the 4th quarter. Nisa Investment Advisors LLC now owns 8,790 shares of the company’s stock worth $48,000 after buying an additional 8,170 shares during the period. RPO LLC bought a new stake in Outset Medical during the fourth quarter valued at about $76,000. Valeo Financial Advisors LLC purchased a new position in shares of Outset Medical in the fourth quarter valued at about $117,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Outset Medical in the fourth quarter valued at about $161,000. About Outset Medical (Get Free Report) Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. Read More Five stocks we like better than Outset Medical Conference Calls and Individual Investors Canada Goose Flies Higher Driven By DTC Growth What is the S&P/TSX Index? CVS Health Stock Has a Silver Lining Called Value ESG Stocks, What Investors Should Know Magnificent 7 Still Magnificent as the Halfway Mark Approaches?
